lorcainide

Lorcainide is a Class Ic antiarrhythmic agent used to restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardia, and Wolff–Parkinson–White syndrome. It acts primarily as a sodium channel blocker, impairing fast sodium conductance in cardiac cells, which suppresses reentry phenomena and ectopic pacemaker activity—especially in the ventricles. Lorcainide can be administered orally or intravenously; it has a prolonged duration of action (8–12 hours) and is well absorbed orally. Its main active metabolite is norlorcainide, which contributes to its antiarrhythmic effects. Lorcainide was withdrawn from the market due to commercial reasons but was later associated with an increased risk of death when used clinically[1][3][4][5][6].

Brand names

Remivox

Other names

lorcainide hydrochlorideN-(4-Chlorophenyl)-N-[1-(1-isopropyl)-4-piperidinyl]phenylacetamide